Robert B. Ford
Chairman and Chief Executive Officer
Abbott Laboratories
Leadership History
5 leaders · Full leadership timeline
Robert B. Ford is the CEO of Abbott Laboratories.
| Name | Role | From | To | Years in role |
|---|---|---|---|---|
| Robert B. Ford | Chairman and Chief Executive Officer | — | Present | — |
| Miles D. White | Executive Chairman (Former CEO) | — | Present | — |
| Robert E. Funck, Jr. | Executive Vice President, Finance and Chief Financial Officer | — | Present | — |
| Michael J. Dale | Executive Vice President, Diabetes Care | — | Present | — |
| Daniel G. Watters | Executive Vice President, Nutritional Products | — | Present | — |
Abbott Laboratories is a towering presence in global healthcare, touching over two billion lives annually through life-changing technologies. Its four core operating pillars—Medical Devices, Diagnostics, Nutritionals, and Established Pharmaceuticals—balance high-growth medtech innovation with stable, recurring consumer healthcare demand.
Abbott operates a diversified, high-margin business model combining consumable medical devices with recurring diagnostic reagent sales and trusted nutritional brands. Over 65% of revenue is derived from recurring consumables and testing supplies.
Chairman and Chief Executive Officer
Executive Chairman (Former CEO)
Executive Vice President, Finance and Chief Financial Officer
Executive Vice President, Diabetes Care
Executive Vice President, Nutritional Products
Key challenges include managing global supply chain resilience, navigating complex international medical device reimbursement reforms, and defending core intellectual property against aggressive medtech competitors.
Robert B. Ford serves as the Chairman and Chief Executive Officer of Abbott Laboratories, having taken the helm in March 2020 after leading Abbott's medical device and diabetes care divisions.
Miles D. White served as Abbott's CEO for 22 years from 1998 to 2020, during which he engineered the 2013 AbbVie spinoff and major medtech acquisitions like St. Jude Medical.
Abbott's current executive team prioritizes scaling consumer biowearables like FreeStyle Libre and Lingo, expanding emerging market footprint, maintaining balance sheet strength, and accelerating digital health innovation.
Abbott maintains robust corporate governance through an independent Board of Directors, rigorous risk management oversight, and transparent ethical compliance standards across all global operations.
Compare executive leadership tenures and strategic transitions
Explore Abbott Laboratories
Core profile pages, founders and related research hubs for this company.